BHC vs. ELAN, ROIV, INSM, ASND, CERE, LEGN, ITCI, VKTX, JAZZ, and BPMC
Should you be buying Bausch Health Companies stock or one of its competitors? The main competitors of Bausch Health Companies include Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Legend Biotech (LEGN), Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Bausch Health Companies (NYSE:BHC) and Elanco Animal Health (NYSE:ELAN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
Bausch Health Companies presently has a consensus price target of $11.33, indicating a potential upside of 80.75%. Elanco Animal Health has a consensus price target of $18.29, indicating a potential upside of 0.42%. Given Bausch Health Companies' higher probable upside, analysts plainly believe Bausch Health Companies is more favorable than Elanco Animal Health.
Bausch Health Companies has a net margin of -5.07% compared to Elanco Animal Health's net margin of -29.83%. Elanco Animal Health's return on equity of 5.98% beat Bausch Health Companies' return on equity.
In the previous week, Elanco Animal Health had 9 more articles in the media than Bausch Health Companies. MarketBeat recorded 12 mentions for Elanco Animal Health and 3 mentions for Bausch Health Companies. Bausch Health Companies' average media sentiment score of 1.74 beat Elanco Animal Health's score of 1.01 indicating that Bausch Health Companies is being referred to more favorably in the media.
Bausch Health Companies has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
78.7% of Bausch Health Companies shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 8.1% of Bausch Health Companies shares are held by company insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Bausch Health Companies received 220 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 61.90% of users gave Bausch Health Companies an outperform vote while only 54.13% of users gave Elanco Animal Health an outperform vote.
Bausch Health Companies has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Summary
Bausch Health Companies beats Elanco Animal Health on 11 of the 18 factors compared between the two stocks.
Get Bausch Health Companies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch Health Companies Competitors List
Related Companies and Tools
